

Martin Prieto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6626117/publications.pdf>

Version: 2024-02-01

187
papers

9,352
citations

46918

47
h-index

39575

94
g-index

208
all docs

208
docs citations

208
times ranked

5866
citing authors

#	ARTICLE	IF	CITATIONS
1	HCV-related fibrosis progression following liver transplantation: increase in recent years. <i>Journal of Hepatology</i> , 2000, 32, 673-684.	1.8	723
2	Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. <i>Hepatology</i> , 2002, 36, 202-210.	3.6	566
3	Natural History of Clinically Compensated Hepatitis C Virus-Related Graft Cirrhosis After Liver Transplantation. <i>Hepatology</i> , 2000, 32, 852-858.	3.6	505
4	High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. <i>Hepatology</i> , 1999, 29, 250-256.	3.6	504
5	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 685-697.	4.6	402
6	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. <i>Hepatology</i> , 2011, 53, 62-72.	3.6	274
7	Clinical Benefits of Antiviral Therapy in Patients with Recurrent Hepatitis C Following Liver Transplantation. <i>American Journal of Transplantation</i> , 2008, 8, 679-687.	2.6	269
8	Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2014, 147, 109-118.e5.	0.6	248
9	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. <i>Liver Transplantation</i> , 2007, 13, 349-360.	1.3	239
10	Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. <i>Hepatology</i> , 2015, 61, 1485-1494.	3.6	206
11	Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. <i>Hepatology</i> , 2003, 38, 1419-1427.	3.6	190
12	A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIG) and lamivudine with long-term lamivudine plus HBIG in the prevention of hepatitis B virus recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2003, 38, 811-817.	1.8	184
13	De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. <i>Liver Transplantation</i> , 2001, 7, 51-58.	1.3	181
14	Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. <i>Journal of Hepatology</i> , 2006, 44, 717-722.	1.8	170
15	Liver transplantation in patients with portal vein thrombosis. <i>Liver Transplantation</i> , 2001, 7, 125-131.	1.3	164
16	Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. <i>Journal of Hepatology</i> , 1998, 28, 756-763.	1.8	163
17	Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2006, 12, 1067-1076.	1.3	154
18	OUTCOME OF AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION1. <i>Transplantation</i> , 1998, 66, 1645-1650.	0.5	139

#	ARTICLE	IF	CITATIONS
19	De Novo Internal Neoplasms after Liver Transplantation: Increased Risk and Aggressive Behavior in Recent Years?. American Journal of Transplantation, 2004, 4, 596-604.	2.6	123
20	Are posttransplantation protocol liver biopsies useful in the long term?. Liver Transplantation, 2001, 7, 790-796.	1.3	122
21	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. Journal of Hepatology, 2016, 65, 532-542.	1.8	115
22	Validation and refinement of survival models for liver retransplantation. Hepatology, 2003, 38, 460-469.	3.6	114
23	Lessons learned from anatomic variants of the hepatic artery in 1,081 transplanted livers. Liver Transplantation, 2007, 13, 1401-1404.	1.3	106
24	Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transplantation, 2003, 9, 228-235.	1.3	104
25	Does the healthy hepatitis C virus carrier state really exist? an analysis using polymerase chain reaction. Hepatology, 1995, 22, 413-417.	3.6	102
26	Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transplantation, 2008, 14, 1449-1460.	1.3	101
27	Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. Journal of Hepatology, 2017, 67, 1168-1176.	1.8	96
28	Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Alimentary Pharmacology and Therapeutics, 2015, 41, 116-125.	1.9	95
29	Adherence to Lamivudine After an Early Withdrawal of Hepatitis B Immune Globulin Plays an Important Role in the Long-Term Prevention of Hepatitis B Virus Recurrence. Transplantation, 2007, 84, 650-654.	0.5	94
30	Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: Results from a multicenter Spanish study. Journal of Hepatology, 2014, 61, 1020-1028.	1.8	90
31	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. Journal of Hepatology, 2017, 66, 718-723.	1.8	90
32	Hyperlipidemia in liver transplant recipients: Prevalence and risk factors. Liver Transplantation, 1997, 3, 416-422.	1.9	87
33	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. Clinical Gastroenterology and Hepatology, 2018, 16, 1495-1502.	2.4	83
34	New concepts and best practices for management of pre- and post-transplantation cancer. Transplantation Reviews, 2012, 26, 261-279.	1.2	82
35	Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transplantation, 2006, 12, 762-767.	1.3	81
36	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa registry. Hepatology, 2017, 65, 1810-1822.	3.6	78

#	ARTICLE	IF	CITATIONS
37	Multiple hepatic adenomas after long-term therapy with testosterone enanthate. <i>Journal of Hepatology</i> , 1985, 1, 573-578.	1.8	76
38	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016, 22, 446-458.	1.3	73
39	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021, 75, 86-97.	1.8	72
40	Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. <i>Hepatology</i> , 1995, 22, 413-7.	3.6	70
41	Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: Impact of donor age and baseline cirrhosis. <i>Liver Transplantation</i> , 2009, 15, 738-746.	1.3	65
42	The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. <i>Transplantation Reviews</i> , 2014, 28, 84-91.	1.2	65
43	Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. <i>Liver Transplantation</i> , 2005, 11, 456-462.	1.3	63
44	Effect of Calcineurin Inhibitors in the Outcome of Liver Transplantation in Hepatitis C Virus-Positive Recipients. <i>Transplantation</i> , 2010, 90, 1204-1209.	0.5	62
45	Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. <i>Liver Transplantation</i> , 2009, 15, 79-87.	1.3	60
46	Liver transplantation in hepatitis C. A Spanish multi-centre experience. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 771-776.	0.8	56
47	Long-term outcome of "long-term liver transplant survivors"™. <i>Transplant International</i> , 2013, 26, 740-750.	0.8	53
48	Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?. <i>Liver Transplantation</i> , 2002, 8, 1020-1027.	1.3	47
49	Delayed onset of severe hepatitis C-related liver damage following liver transplantation: A matter of concern?. <i>Liver Transplantation</i> , 2003, 9, 1152-1158.	1.3	47
50	Gastrointestinal Complications in Liver Transplant Recipients: MITOS Study. <i>Transplantation Proceedings</i> , 2007, 39, 2311-2313.	0.3	46
51	Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preclin study. <i>PLoS ONE</i> , 2017, 12, e0184550.	1.1	45
52	Incidence and outcome of De Novo malignancies after liver transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 1275-1277.	0.3	44
53	Comparison of two non-contemporaneous HCV-liver transplant cohorts: Strategies to improve the efficacy of antiviral therapy. <i>Journal of Hepatology</i> , 2012, 56, 1310-1316.	1.8	42
54	Diagnosis of malignant ascites. <i>Digestive Diseases and Sciences</i> , 1988, 33, 833-838.	1.1	41

#	ARTICLE	IF	CITATIONS
55	Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. <i>Liver Transplantation</i> , 2015, 21, 812-822.	1.3	39
56	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
57	Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. <i>Liver Transplantation</i> , 1999, 5, 246-248.	1.9	38
58	Recurrent hepatitis C genotype 1b following liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1207-1212.	0.8	37
59	Chronic Kidney Disease After Liver Transplantation. <i>Transplantation</i> , 2013, 95, 1148-1153.	0.5	35
60	Does HLA matching influence accelerated progression of hepatitis C following liver transplantation in genotype 1b infection?. <i>Journal of Hepatology</i> , 2000, 32, 51.	1.8	34
61	Study on the Efficacy and Safety of Adefovir Dipivoxil Treatment in Post-Liver Transplant Patients With Hepatitis B Virus Infection and Lamivudine-Resistant Hepatitis B Virus. <i>Transplantation Proceedings</i> , 2005, 37, 3960-3962.	0.3	34
62	Cyclosporine A-Based Immunosuppression Reduces Relapse Rate After Antiviral Therapy in Transplanted Patients With Hepatitis C Virus Infection: A Large Multicenter Cohort Study. <i>Transplantation</i> , 2011, 92, 334-340.	0.5	34
63	227 LONG-TERM RESULTS WITH THE USE OF GRAFTS FROM HBSAG NEGATIVE HBCAB POSITIVE DONORS IN LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2008, 48, S93.	1.8	32
64	Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. <i>Liver Transplantation</i> , 2014, 20, 25-34.	1.3	31
65	Bacteriuria in patients with cirrhosis. <i>Journal of Hepatology</i> , 1992, 16, 73-76.	1.8	29
66	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 535-542.	0.8	25
67	O62 SOFOSBUVIR COMPASSIONATE USE PROGRAM FOR PATIENTS WITH SEVERE RECURRENT HEPATITIS C INCLUDING FIBROSING CHOLESTATIC HEPATITIS FOLLOWING LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2014, 60, S26.	1.8	25
68	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 779-789.	1.1	25
69	Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. <i>Transplant International</i> , 2006, 19, 641-648.	0.8	24
70	Comparative prospective study of two liver graft preservation solutions: University of Wisconsin and Celsior. <i>Liver Transplantation</i> , 2009, 15, 1709-1717.	1.3	24
71	Budd-Chiari syndrome caused by membranous obstruction of the inferior vena cava associated with coeliac disease. <i>Digestive and Liver Disease</i> , 2004, 36, 157-162.	0.4	23
72	Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection. <i>Transplantation</i> , 2016, 100, 1507-1512.	0.5	23

#	ARTICLE	IF	CITATIONS
73	Prospective assessment of donor blood screening for antibody to hepatitis B core antigen as a means of preventing posttransfusion non-A, non-B, hepatitis. <i>Hepatology</i> , 1989, 9, 449-451.	3.6	22
74	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 945-949.e1.	2.4	22
75	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 226-237.	1.0	22
76	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 414-422.	0.7	21
77	Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covid-19. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1853-1853.	1.4	21
78	Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. <i>Liver Transplantation</i> , 2009, 15, 1798-1807.	1.3	20
79	Impact of hepatitis C virus (<sc>HCV</sc>) antiviral treatment on the need for liver transplantation (<sc>LT</sc>). <i>Liver International</i> , 2018, 38, 1022-1027.	1.9	20
80	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 559-587.	0.0	20
81	Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2004, 10, 217-227.	1.3	19
82	Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: Role of an aggressive approach. <i>Liver Transplantation</i> , 2013, 19, 69-77.	1.3	18
83	Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 159-168.	1.0	18
84	Iberogast-Induced Severe Hepatotoxicity Leading to Liver Transplantation. <i>American Journal of Gastroenterology</i> , 2016, 111, 1364-1365.	0.2	18
85	Documento de consenso de la Asociación Española para el Estudio del Hígado sobre el tratamiento de la infección por el virus de la hepatitis B (2020). <i>Gastroenterología Y Hepatología</i> , 2020, 43, 559-587.	0.2	18
86	The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. <i>BMC Infectious Diseases</i> , 2017, 17, 45.	1.3	17
87	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 999.	0.8	16
88	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young to the Old. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1147-1158.	2.3	16
89	Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. <i>Liver International</i> , 2018, 38, 1940-1950.	1.9	15
90	Albumin dialysis with MARS for the treatment of anabolic steroid-induced cholestasis. <i>Annals of Hepatology</i> , 2016, 15, 939-943.	0.6	15

#	ARTICLE	IF	CITATIONS
91	Famciclovir Treatment in Transplant Recipients With Hbv-Related Liver Disease: Disappointing Results. American Journal of Gastroenterology, 2001, 96, 526-533.	0.2	14
92	Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation. Journal of Viral Hepatitis, 2006, 13, 104-115.	1.0	13
93	Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. Liver Transplantation, 2011, 17, 1318-1327.	1.3	13
94	Indications for and Results of Liver Retransplantation. Transplantation Proceedings, 2009, 41, 1016-1017.	0.3	12
95	Comparison of results of combined liver-kidney transplantation vs. isolated liver transplantation. Annals of Hepatology, 2013, 12, 274-281.	0.6	12
96	Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients. European Journal of Gastroenterology and Hepatology, 2019, 31, 267-271.	0.8	12
97	Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction*1. Hepatology, 1995, 22, 413-417.	3.6	11
98	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. Liver International, 2017, 37, 1823-1832.	1.9	10
99	Antibody to hepatitis B core antigen-positive grafts: Not perfect but no longer marginal. Liver Transplantation, 2009, 15, 1164-1168.	1.3	9
100	Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. Annals of Hepatology, 2013, 12, 974-978.	0.6	9
101	Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin. Transplant Infectious Disease, 2015, 17, 208-220.	0.7	9
102	Association of Cardiac Abnormalities to the Frail Phenotype in Cirrhotic Patients on the Waitlist. Transplantation, 2018, 102, e101-e107.	0.5	9
103	VI documento de consenso de la sociedad espaÃ±ola de trasplante hepÃ¡tico (SETH). GastroenterologÃ­a Y HepatologÃ­a, 2018, 41, 406-421.	0.2	9
104	Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry. Journal of Hepatology, 2016, 64, S133.	1.8	8
105	Effectiveness and Safety of Sofosbuvir/Ledipasvir Treatment for Monoinfected Genotype 1 HCV Patients in Real-Life Clinical Practice: Results from Spanish Hepa-C Cohort. Journal of Hepatology, 2016, 64, S217-S218.	1.8	8
106	Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World Journal of Gastroenterology, 2017, 23, 7459-7469.	1.4	8
107	Hepatitis C virus viral kinetics during Î±-2a or Î±-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimens. Journal of Clinical Virology, 2012, 53, 231-238.	1.6	7
108	Effectiveness and Safety of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir Patients with Genotype 1 Chronic Hepatitis C Virus Infection: Results from the Spanish Real World Cohort. Journal of Hepatology, 2016, 64, S218-S219.	1.8	7

#	ARTICLE	IF	CITATIONS
109	Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study. <i>Transplant International</i> , 2018, 31, 649-657.	0.8	7
110	74 THE ANTIVIRAL RESPONSE TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IS COMPARABLE IN LAMIVUDINE (LAM)-NAIVE AND LAM-EXPERIENCED SUBJECTS TREATED FOR CHRONIC HEPATITIS B (CHB). <i>Journal of Hepatology</i> , 2008, 48, S33.	1.8	6
111	923 SAFETY AND EFFICACY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE THERAPY IN LAMIVUDINE EXPERIENCED PATIENTS. <i>Journal of Hepatology</i> , 2009, 50, S335-S336.	1.8	6
112	Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. <i>Transplant International</i> , 2017, 30, 1041-1050.	0.8	6
113	Hepatitis C Viral Infection after Orthotopic Liver Transplantation. <i>Advances in Experimental Medicine and Biology</i> , 1994, 368, 173-179.	0.8	6
114	FRI-225-Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection. <i>Journal of Hepatology</i> , 2019, 70, e493-e494.	1.8	5
115	129 The five year follow-up of a randomized study comparing lamivudine with lamivudine+HBIG investigating the prevention of HBV recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2006, 44, S57.	1.8	4
116	P1040 TENOFOVIR FOR THE PROPHYLAXIS OF HBV REACTIVATION IN ANTI-HBC-POSITIVE PATIENTS WITH HEMATOLOGIC MALIGNANCIES TREATED WITH RITUXIMAB: PRELIMINARY RESULTS OF A RANDOMIZED STUDY (PREBLIN STUDY). <i>Journal of Hepatology</i> , 2014, 60, S421-S422.	1.8	4
117	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 46-54.	0.8	4
118	Efficacy and Tolerability of Interferon-Free Antiviral Therapy in Kidney Transplant (KT) Recipients with Chronic Hepatitis C: Real-Life Data from the Spanish National Registry (HEPA-C). <i>Journal of Hepatology</i> , 2016, 64, S793-S794.	1.8	4
119	Interferon (INF)-Free Antiviral Therapy in Cirrhotic Patients Infected with Hepatitis C on the Waiting List for Liver Transplantation. Efficacy and Impact on Delisting and Liver Function. <i>Journal of Hepatology</i> , 2016, 64, S543.	1.8	4
120	VI documento de consenso de la sociedad espa�ola de trasplante hep�tico (SETH). <i>Cirug�a Espa�ola</i> , 2018, 96, 326-341.	0.1	4
121	Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. <i>Transplantation Proceedings</i> , 2016, 48, 3013-3016.	0.3	3
122	Prevents HBV Reactivation with Tenofovir in Anti-HBC Positive Patients with Hematologic Malignancies Treated with Rituximab. Results Final Visit 18-Months (Preblin Study). <i>Journal of Hepatology</i> , 2016, 64, S369.	1.8	3
123	DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome. <i>Journal of Hepatology</i> , 2018, 68, S601.	1.8	3
124	94 CALCINEURIN INHIBITORS AND OUTCOME OF LIVER TRANSPLANTATION IN HCV-POSITIVE RECIPIENTS: FINAL RESULTS OF A PROSPECTIVE RANDOMIZED STUDY. <i>Journal of Hepatology</i> , 2010, 52, S43.	1.8	2
125	Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4. <i>Journal of Hepatology</i> , 2016, 64, S831.	1.8	2
126	Effectiveness of Daclatasvir Based Therapy in Patients with Chronic Hepatitis C in Europe: Experience from the Named Patient Program. <i>Journal of Hepatology</i> , 2016, 64, S801.	1.8	2

#	ARTICLE	IF	CITATIONS
127	Peritransplant Antiviral Treatment of Human Immunodeficiency Virus/Hepatitis C Virus-Infected Patients. Liver Transplantation, 2018, 24, 1476-1480.	1.3	2
128	Post-transplantation (LT) significant HCV-related disease severity: Increase in recent years. Journal of Hepatology, 2000, 32, 34.	1.8	1
129	Prolonged follow-up of HBV liver transplanted patients: results from a randomized study comparing lamivudine vs. lamivudine+HBIG in the prevention of HBV recurrence after liver transplantation. Journal of Hepatology, 2003, 38, 37.	1.8	1
130	[137] RESPONSE TO PEGYLATED INTERFERON-RIBAVIRIN IN PATIENTS WITH RECURRENT HEPATITIS C IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR MIXED (ALCOHOL-HCV) CIRRHOSIS. Journal of Hepatology, 2007, 46, S62.	1.8	1
131	Indications and results of liver retransplantation: experience with 1181 patients in the hospital universitario La Fe. CirugÃa EspaÃ±ola (English Edition), 2010, 87, 356-363.	0.1	1
132	451 NO IMPACT OF OBESITY ON POST-LIVER TRANSPLANTATION OUTCOME AMONG HCV-INFECTED LIVER TRANSPLANT RECIPIENTS. Journal of Hepatology, 2010, 52, S183.	1.8	1
133	P1200 EFFECTIVENESS OF TRIPLE THERAPY WITH BOCEPREVIR OR TELAPREVIR IN A MULTICENTRE CLINICAL PRACTICE COHORT OF HCV TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED HEPATIC FIBROSIS. SVR-12W AFTER TREATMENT. Journal of Hepatology, 2014, 60, S488.	1.8	1
134	P1041 TENOFOVIR MONOTHERAPY VERSUS LAMIVUDINE PLUS ADEFOVIR IN LAMIVUDINE-FAILURE PATIENTS RESCUED WITH LAMIVUDINE PLUS ADEFOVIR COMBINATION: INTERIM ANALYSIS OF THE TENOSIMP-B CLINICAL TRIAL. Journal of Hepatology, 2014, 60, S422.	1.8	1
135	P1207 TRIPLE THERAPY FOR HCV CIRRHOSIS IN LIVER TRANSPLANT CANDIDATES. HIGH RATE OF PREVENTION OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION (LT) IN WELL SELECTED PATIENTS. Journal of Hepatology, 2014, 60, S490.	1.8	1
136	P1097 : Distinguishing drug induced autoimmune hepatitis from idiopathic autoimmune hepatitis. Journal of Hepatology, 2015, 62, S761.	1.8	1
137	P0649 : Characterization of HBsAg loss in patients with chronic hepatitis B (CHB) treated with nucleos(tide) analogs (NUCs): A retrospective multicenter study (HEBESAS). Journal of Hepatology, 2015, 62, S563-S564.	1.8	1
138	Efficacy and Clinical Impact of Daclatasvir-Based Antiviral Therapy in Severe Recurrent Hepatitis C after Liver Transplantation. Results from a Multicenter Spanish Group. Journal of Hepatology, 2016, 64, S547.	1.8	1
139	Ledipasvir/Sofosbuvir for Recurrent Hepatitis C in Liver Transplant Recipients: A Real-Life Spanish Multicentre Experience. Journal of Hepatology, 2016, 64, S794-S795.	1.8	1
140	VI Consensus Document by the Spanish Liver Transplantation Society. CirugÃa EspaÃ±ola (English) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50	0.1	1
141	Alarming decrease in patient survival among HCV-infected liver transplant recipients. Journal of Hepatology, 2001, 34, 32-33.	1.8	1
142	Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications. Revista Espanola De Enfermedades Digestivas, 1997, 89, 531-50.	0.1	1
143	Comparative analysis of quantification of viral load in patients infected with hepatitis C virus: quantiplex HCV RNA assay and amplicor monitor assay. Revista Espanola De Enfermedades Digestivas, 1999, 91, 569-82.	0.1	1
144	Hepatocellular carcinoma (HCC): Can it still be considered a controversial indication for liver transplantation (LT)?. Journal of Hepatology, 2000, 32, 53.	1.8	0

#	ARTICLE	IF	CITATIONS
145	Are post-transplantation protocol liver biopsies useful in the longterm. Journal of Hepatology, 2000, 32, 53.	1.8	0
146	Retransplant of the liver (RLT) in recurrent hepatitis C virus (HCV)infection: Retrospective multicentric study. Journal of Hepatology, 2000, 32, 55.	1.8	0
147	Potential reduction of post-transplantation HCV-related disease progression by a better selection of the donor. Journal of Hepatology, 2002, 36, 175-176.	1.8	0
148	Severe recurrent hepatitis C following liver transplantation (OLT): treatment with combination interferon-ribavirin therapy (CT). Journal of Hepatology, 2002, 36, 187.	1.8	0
149	Genetic heterogeneity in immunogenic epitopes of the hepatitis C virus NS3 protein in liver transplant recipients with recurrent hepatitis C. Journal of Hepatology, 2003, 38, 114.	1.8	0
150	102 Preliminary data for the treatment of adefovir in transplant patients with hepatitis B (HBV) resistant to lamivudine. Journal of Hepatology, 2004, 40, 38.	1.8	0
151	422 Efficacy and safety of adefovir for the treatment of patients with chronic hepatitis B (CHB) resistant to lamivudine in Spain. Journal of Hepatology, 2004, 40, 125.	1.8	0
152	127 Liver transplantation for HCV-alcohol aetiology: Is the outcome similar to those to HCV or alcohol alone?. Journal of Hepatology, 2006, 44, S56-S57.	1.8	0
153	450 LOW EFFICACY OF ANTIVIRAL THERAPY IN HCV-LIVER TRANSPLANT RECIPIENTS TREATED AT ADVANCED STAGES OF FIBROSIS. Journal of Hepatology, 2010, 52, S183.	1.8	0
154	490 IMPACT OF OBESITY ON SURVIVAL IN PATIENTS UNDERGOING LIVER TRANSPLANTATION. Journal of Hepatology, 2010, 52, S198.	1.8	0
155	Management of hepatitis B virus infection in the pre-transplant setting. Digestive and Liver Disease Supplements, 2011, 5, 10-14.	0.2	0
156	517 POST-LIVER TRANSPLANTATION (LT) OUTCOME IN HIV/HCV CO-INFECTED PATIENTS. COMPARISON WITH MONOINFECTED PATIENTS WITH HCV-CIRRHOSIS. Journal of Hepatology, 2011, 54, S212.	1.8	0
157	521 PATIENTS SURVIVING AT LEAST 10 YEARS POST LIVER TRANSPLANTATION: LONG TERM COMPLICATIONS. Journal of Hepatology, 2011, 54, S213-S214.	1.8	0
158	540 VALIDATION OF A PREDICTIVE MODEL FOR CHRONIC RENAL DYSFUNCTION FOLLOWING LIVER TRANSPLANTATION. Journal of Hepatology, 2011, 54, S221.	1.8	0
159	806 TRIPHASIC VIRAL LOAD KINETICS OF HEPATITIS C VIRUS DURING ANTIVIRAL THERAPY POST-TRANSPLANTATION: EFFECT OF THE TYPE OF PEGYLATED-IFN AND BASELINE IMMUNOSUPPRESSION. Journal of Hepatology, 2011, 54, S323-S324.	1.8	0
160	195 LONG-TERM OUTCOME OF LIVER TRANSPLANTATION FOR HEPATITIS B WITH ANTI-HBC POSITIVE GRAFTS. Journal of Hepatology, 2012, 56, S83-S84.	1.8	0
161	236 SEXUAL DYSFUNCTION IN CIRRHOTIC PATIENTS AWAITING LIVER TRANSPLANTATION. Journal of Hepatology, 2013, 58, S101-S102.	1.8	0
162	915 WORSE TOLERABILITY OF TRIPLE THERAPY IN SPECIAL POPULATIONS: CIRRHOTICS AND LIVER TRANSPLANT RECIPIENTS. Journal of Hepatology, 2013, 58, S377.	1.8	0

#	ARTICLE	IF	CITATIONS
163	1225 TOLERABILITY TO ANTIVIRAL DUAL AND TRIPLE THERAPY IN LIVER TRANSPLANT RECIPIENTS. <i>Journal of Hepatology</i> , 2013, 58, S497.	1.8	0
164	P1198 EFFECTIVENESS OF TRIPLE THERAPY IN CLINICAL PRACTICE FOR TREATMENT-NAIVE HCV PATIENTS WITH ADVANCED HEPATIC FIBROSIS. VIROLOGIC RESPONSE DATA AT 12 WEEKS POST-TREATMENT (SVR-12W). <i>Journal of Hepatology</i> , 2014, 60, S486-S487.	1.8	0
165	P310 ANABOLIC ANDROGENIC STEROIDS (AAS) ILLICIT USE IS A RAPIDLY GROWING CAUSE OF DRUG-INDUCED LIVER INJURY (DILI): A PROSPECTIVE SERIES FROM THE SPANISH AND LATIN-AMERICAN DILI REGISTRY. <i>Journal of Hepatology</i> , 2014, 60, S169.	1.8	0
166	P1196 ADVERSE EFFECTS OF TRIPLE THERAPY WITH BOCEPREVIR (BOC) AND TELAPREVIR (TVR) IN CLINICAL PRACTICE IN PATIENTS WITH ADVANCED HEPATIC FIBROSIS. <i>Journal of Hepatology</i> , 2014, 60, S485-S486.	1.8	0
167	P910 IMPACT OF ANEMIA IN VIRAL RESPONSE DURING TRIPLE THERAPY IN LIVER TRANSPLANT RECIPIENTS. <i>Journal of Hepatology</i> , 2014, 60, S378.	1.8	0
168	P1143 APPLICABILITY OF TRIPLE THERAPY IN CIRRHOTIC POPULATION: VALIDATION OF CUPIC DATA. <i>Journal of Hepatology</i> , 2014, 60, S463.	1.8	0
169	P309 PROGNOSTIC MODEL FOR PREDICTING DRUG-INDUCED ACUTE LIVER FAILURE. <i>Journal of Hepatology</i> , 2014, 60, S169.	1.8	0
170	P894 PROPHYLAXIS OF DE NOVO HEPATITIS B VIRUS INFECTION WITH LAMIVUDINE IN HBsAg-NEGATIVE NAIVE RECIPIENTS OF HEPATITIS B CORE ANTIBODY-POSITIVE LIVERS: A 13-YEAR SINGLE-CENTER EXPERIENCE. <i>Journal of Hepatology</i> , 2014, 60, S372.	1.8	0
171	P0654 : Long-term sustained suppression of viral replication is associated with low HBsAg levels in patients with chronic hepatitis B (CHB) treated with nucleos(T)ide analogues (NUCs). <i>Journal of Hepatology</i> , 2015, 62, S565-S566.	1.8	0
172	P0785 : First real clinical practice data in Spain on sofosbuvir, simeprevir and daclatasvir in post-transplant HCV recurrence: The HepatiC registry experience. <i>Journal of Hepatology</i> , 2015, 62, S626.	1.8	0
173	Distinguishing Drug-induced Autoimmune Hepatitis from idiopathic Autoimmune Hepatitis and Dili with Autoantibodies. <i>Clinical Therapeutics</i> , 2015, 37, e115-e116.	1.1	0
174	Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Genotype 1, after Liver Transplantation: Efficacy and Safety. <i>Journal of Hepatology</i> , 2016, 64, S538-S539.	1.8	0
175	Peri-Transplant Treatment with Direct-Acting Antivirals of HIV-HCV Coinfected Patients. <i>Journal of Hepatology</i> , 2016, 64, S552.	1.8	0
176	Treatment Discontinuation after HBsAg Loss is Safe in Chronic Hepatitis B Patients Treated with Nucleos/Tide Analogs: A Retrospective Multicenter Study (HEBESAS). <i>Journal of Hepatology</i> , 2016, 64, S588.	1.8	0
177	Clinical characteristics and outcomes of elderly included in the Spanish Drug-Induced Liver Injury (DILI) Registry. <i>Journal of Hepatology</i> , 2017, 66, S399.	1.8	0
178	Idiosyncratic Drug-Induced Liver Injury: A 20-Year Update of the Cases Enrolled By the Spanish Dili Registry. <i>Clinical Therapeutics</i> , 2017, 39, e57.	1.1	0
179	Effectiveness of ribavirin use associated with direct-acting antivirals in the treatment of non-cirrhotic patients with genotype 1a or 4 HCV infection in real-world practice. <i>Journal of Hepatology</i> , 2017, 66, S523-S524.	1.8	0
180	Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study. <i>Journal of Hepatology</i> , 2017, 66, S718-S719.	1.8	0

#	ARTICLE	IF	CITATIONS
181	The use of prophylactic strategies using hepatitis B immunoglobulin for hepatitis B recurrence after liver transplantation in routine clinical practice in Spain. Preliminary results of the 1st round of a delphi panel. <i>Journal of Hepatology</i> , 2017, 66, S190.	1.8	0
182	HCV cirrhosis: liver volume as a non-invasive predictor of liver recovery post DAA treatment. <i>Journal of Hepatology</i> , 2017, 66, S574.	1.8	0
183	Clinical outcomes of patients delisted from the waiting list of liver transplantation after interferon-free antiviral therapy. <i>Journal of Hepatology</i> , 2017, 66, S186.	1.8	0
184	Out of Milan criteria and worse intetion to treat results at large liver transplant center. <i>Journal of Hepatology</i> , 2018, 68, S201-S202.	1.8	0
185	VI consensus document by the Spanish Liver Transplantation Society. <i>GastroenterologĀa Y HepatologĀa</i> (English Edition), 2018, 41, 406-421.	0.0	0
186	THU-124-Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C). <i>Journal of Hepatology</i> , 2019, 70, e213-e214.	1.8	0
187	Cardiovascular risk and liver transplantation in HIV patients. Are HIV infected liver transplant recipients at higher risk?. <i>Journal of Liver Transplantation</i> , 2021, 1, 100005.	0.2	0